跳至主要内容
临床试验/EUCTR2021-002011-61-NL
EUCTR2021-002011-61-NL进行中(未招募)1 期

The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome - Riluzole in 22q11.2DS

Academisch ziekenhuis Maastricht0 个研究点目标入组 45 人开始时间: 2021年6月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Confirmed diagnosis of 22q11.2 deletion syndrome established by FISH, microarray or MLPA analysis.
  • 16 year or older of age and mentally competent (determined by an experienced physician) to give informed consent.
  • Presence of psychotic and/or cognitive symptoms (defined as a score of =4, moderately ill, on the Clinical Global Impression-Schizophrenia Scale (CGI-SCH)).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Other chromosomal abnormalities.
  • - Current substance abuse / dependence.
  • - Use of first-generation antipsychotics or clozapine.
  • - Contraindications for MRI.
  • - Contraindications for riluzole.
  • - Pregnancy.

研究者

相似试验